MTD of ixabepilone defined as the first dosage tier below the MAD in which =< 1/6 patients experiences a DLT 28 days [clinicaltrials_resource:4b5ecf03b9856401c8fc87ccbb80b08f]
Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
MTD of ixabepilone defined as the first dosage tier below the MAD in which =< 1/6 patients experiences a DLT 28 days [clinicaltrials_resource:4b5ecf03b9856401c8fc87ccbb80b08f]
Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
Bio2RDF identifier
4b5ecf03b9856401c8fc87ccbb80b08f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4b5ecf03b9856401c8fc87ccbb80b08f
measure [clinicaltrials_vocabulary:measure]
MTD of ixabepilone defined as ...... 1/6 patients experiences a DLT
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive BMS-247550 IV ...... or up to a total of 6 courses
identifier
clinicaltrials_resource:4b5ecf03b9856401c8fc87ccbb80b08f
title
MTD of ixabepilone defined as ...... ents experiences a DLT 28 days
@en
type
label
MTD of ixabepilone defined as ...... ecf03b9856401c8fc87ccbb80b08f]
@en